AAV Apex Suite
AAV
APEX suite
An engineered suite of tools for end-to-end AAV production
AAV Apex Suite delivers a high yield AAV production system designed to improve manufacturing efficiency, quality, and scalability across serotypes, payloads and production scales. The suite is build to help make more gene therapy programs feasible — starting with engineered production cell lines and expanding over time with additional production-enabling technologies.
Transient Production [Stable Production
Coming Soon](https://64xbio.com/aavapexsuite#stable_production)
TRANSIENT PRODUCTION
overview
We offer transient cell line products that have been independently confirmed by leading pharmaceutical companies and CDMOs across multiple scales, serotypes and therapeutic payloads, at high titer and quality.
Suspension-adapted HEK293 clonal cell line
Suspension-adapted in chemically defined media.
Fast recovery, fast doubling time, and non-aggregated.
Documented monoclonality.
High quality research grade available, GMP grade coming soon.
High titers across multiple AAV serotypes
Independently confirmed by partners, our cell lines deliver consistently high yields and high quality AAV, with titers exceeding E15 vg/L across a range of AAV serotypes, using a commercially available plasmid system and GFP payload.
Licensing & Partnerships
License our AAV Apex Suite cell line for your gene therapy program, or partner with 64x to develop custom products using VectorSelect.
Stable PRODUCTION Coming Soon
Using VectorSelect, we are developing the next generation of gene therapy production with stable production technologies.
General: info@64xbio.com
Licensing & Partnerships: bd@64xbio.com